Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder

• Váldodahkkit: Hironobu Ichikawa (Dahkki), Tasuku Miyajima (Dahkki), Yushiro Yamashita (Dahkki), Masakazu Fujiwara (Dahkki), Akimasa Fukushi (Dahkki), Kazuhiko Saito (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2020-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Aims As an extension of a phase 2/3 study evaluating the efficacy and safety of lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d for 4 weeks in Japanese patients aged 6‐17 years with attention‐deficit/hyperactivity disorder (ADHD), this study evaluated its long‐term safety and efficacy....